Sonire Therapeutics started a U.S.-based Sunrise II study of its Suizenji ultrasound-guided high-intensity focused ultrasound (HIFU) system to ablate pancreatic tumors after closing an $18 million Series A round. The study adds U.S. execution for a platform designed to deliver targeted energy to tumors while reducing collateral exposure. The move signals Sonire’s shift toward clinical validation in a major market where pancreatic cancer outcomes depend on earlier detection and effective local control. In parallel, the company’s financing history indicates continued investor appetite for next-generation procedural oncology technologies.